News >

Paradigm Shift Still Leaves Unanswered Questions in Stage III NSCLC

Jessica Hergert
Published: Thursday, Nov 21, 2019

Everett E. Vokes, MD, the John E. Ultmann Professor of Medicine and Radiation Oncology, and physician-in-chief and chair of the Department of Medicine at University of Chicago Medicine

Everett E. Vokes, MD
Results of the randomized phase III PACIFIC trial introduced a new standard of care with durvalumab (Imfinzi) after chemoradiation for patients with locally advanced, unresectable non–small cell lung cancer (NSCLC). However, following these data, questions remain regarding sequencing and what patient subsets best respond to the PD-L1 inhibitor, said Everett E. Vokes, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication